A-431 + EGF nuclear extract: sc-2124

The A-431 + EGF nuclear extract is derived from A-431 cells, which are human epidermoid carcinoma cells, treated with epidermal growth factor (EGF). This treatment stimulates EGF receptor (EGFR) signaling, a key pathway in cellular growth and differentiation, particularly in epithelial tissues. The nuclear extract contains a concentrated sample of nuclear proteins, including transcription factors, signal transducers, and other regulatory proteins that respond to EGF stimulation. By focusing on these components, researchers can study the direct effects of EGF on nuclear function and gene expression dynamics within a cancerous epithelial cell context. The A-431 + EGF nuclear extract is extensively used to explore the nuclear signaling mechanisms of EGFR, including the transcriptional responses initiated by EGF binding to its receptor, which often leads to alterations in cell cycle regulation, apoptosis, and other cellular behaviors critical for cancer progression and cellular response to environmental cues. Studies utilizing this nuclear extract help delineate how EGF-induced signaling pathways converge on the nucleus to modulate gene expression patterns and cellular outcomes. This research is particularly valuable in understanding the molecular basis of cell proliferation and survival, offering insights into the regulation of these processes in both normal epithelial and cancerous cells.

A-431 + EGF nuclear extract References:

1. Epidermal growth factor activation of NF-kappaB is mediated through IkappaBalpha degradation and intracellular free calcium.  |  Sun, L. and Carpenter, G. 1998. Oncogene. 16: 2095-102. PMID: 9572490